We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Does Not Give Denosumab Priority Review
FDA Does Not Give Denosumab Priority Review
February 20, 2009
The FDA is giving Amgen’s denosumab a 10-month review period although the company requested priority review for its BLA.